Diffuse intrinsic pontine glioma tumor-associated antigens (DIPG TAAs)

Diffuse intrinsic pontine glioma (DIPG) tumor-associated antigens (TAAs) represent a diverse pool of peptides derived from the tumor proteome, often including the hallmark H3K27M mutation, which are processed and presented on Major Histocompatibility Complex (MHC) molecules. These antigens serve as the primary recognition signals for T-cell receptors (TCRs), facilitating the identification and destruction of glioma cells by the adaptive immune system. In therapeutic contexts, DIPG lysate is frequently used to pulse dendritic cells or create vaccines, providing a broad spectrum of targets to overcome tumor heterogeneity and prevent immune escape. This approach aims to bypass the highly immunosuppressive microenvironment of the pons by priming systemic T-cell responses that can cross the blood-brain barrier. Clinical strategies focusing on these antigens are currently being evaluated to address the lack of effective conventional treatments for this aggressive pediatric brain tumor.

Other names

DIPG lysate-derived antigensDiffuse intrinsic pontine glioma lysateDIPG-associated peptidesH3K27M-associated tumor antigens

Induction of a polyclonal T-cell response against multiple tumor-specific and tumor-associated epitopes presented on MHC molecules to eliminate malignant cells.